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Summary: A pharmaceutical company, Global Pharma (fictitious name), has strong presence 
in the western markets of Europe and the US, where the major manufacturing base is also 
located.  With the shift in growth from these developed markets to the emerging markets of 
Asia, Latin America, Eastern Europe and Middle East Africa, there is a resulting increase in 
transportation of goods and hence cost and carbon footprint. At the same time, the company 
has opportunities to reduce these costs because localizing manufacturing in emerging markets 
offers will reduce the transportation costs and the carbon footprint. However, it requires 
significant investment and long-term planning for a pharmaceutical company to determine 
the viability to localize its manufacture in emerging markets. Localization is establishing one 
or more of a company’s functions in a country. These functions include and not limited to, 
manufacturing, research and development, warehousing, and procurement. In this study, we 
develop a framework to assist a pharmaceutical company in the localization decision-making. 
In the framework, a comprehensive list of key external factors are obtained and analyzed for 
their impact on localization in a particular market. Those factors are also grouped into 
pertinent categories that are arranged into logical levels according to their importance and the 
degree of the company’s control over them. We apply the framework for the localization 
decisions in Malaysia and Indonesia and the application of this framework infers that the 
atmosphere in the two countries is positive for localization. 
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Introduction 
 
The company, Global Pharma (fictitious 
name), is a global pharmaceutical products 
manufacturer with strong emphasis in 
commercial pharmaceutical products. The 
company has a strong presence in North 
America, Europe, and Japan and is 
establishing a strong presence in the 
emerging markets. Global Pharma 
performs extensive research to develop 
innovative pharmaceuticals to treat 
ailments for which there are few 
affordable treatment options. The company 
is also committed to provide access to 
affordable healthcare to the broader 
population. The purpose of this thesis is to 
develop a framework that will assist 
Global Pharma in localization decisions. 
Localization is a process in which a 
company sets up one or more of its 
functions in a country. These functions can 
be manufacturing, research and 
development, services, purchasing, etc. 
Driving Factors for Localization 
The factors that are driving a company to 
localize are presented below. 
 
Research Questions and Scope 
This thesis aims to answer the following 
research questions: 
(1) What are the key external factors 
that influence the localization 
decisions? 
(2) What is the framework that will 
assist Global Pharma in the 
localization decision-making? 
After a framework that assists in 
localization decisions is developed, it will 
be applied to Malaysia and Indonesia. 
Literature Review 
Several external factors are identified and 
they are arranged into following 
categories: 
Push Factors 
•  Increased 
transporation 
to ship 
finished 
products to 
emerging 
markets 
•  Increased 
transportation 
to procure raw 
materials from 
emerging 
markets 
•  Increased 
carbon 
footprint 
Pull Factors 
•  Growth in 
the emerging 
markets 
•  Affordable 
labor force 
•  Improving 
infrastructure 
•  Availability 
of skilled 
workforce 
•  Lower raw 
material 
costs 
KEY DEVELOPMENTS: 
 
1. Emerging markets provide 
opportunities for a pharmaceutical 
company to provide greater access 
to medicines for broader 
population. 
2. A list of key external factors that 
influence localization decisions. 
3. A qualitative analysis of factors 
determining their impact. 
4. Categorization of factors into 
pertinent groups. 
5. A framework that will use a 
hierarchal or level approach that 
will assist in localization decisions. 
6. An application of framework to 
Malaysia and Indonesia. 
 
Examples of key factors under each 
category are presented in the table below. 
Category Factors 
Government 
Policy 
Tendering, Tax Incentives, 
Business Approval Process 
Regulatory 
Affairs 
Patent Protection, Quality 
Assurance and Quality 
Control Requirements, 
Regulatory Requirements 
Technology 
and Trade 
Policy 
Production Technology, 
Tracking Technology, Trade 
Policy 
Demographics Gross Domestic Product, 
Population Density, Peoples 
beliefs in Foreign vs. Local 
Competitors Existing Competitors, 
Competitors’ Market Share, 
Competitors’ Growth 
Foreign 
Direct 
Investment 
History of Foreign Direct 
Investment (FDI), 
atmosphere for FDI. 
Longevity and 
Growth 
Market Stability, Market 
Conditions, Market Trends 
Supply Chain Infrastructure, Reliable 
Supplier Network, 
Customer Expectations 
 
Contributions of this thesis: 
(1) A comprehensive list of key factors 
that influence the localization 
decisions for the pharmaceutical 
companies in emerging markets.  
(2) Categorization of factors and 
prioritizing categories.  
(3) Identifying the impact of the 
factors as positive, negative or 
unknown using literature. 
(4) A decision framework that uses 
categories and impact to support 
localization decisions. 
 
Research Method 
 
 
Applications of Framework to Malaysia 
and Indonesia 
The following table presents the 
applications of framework to Malaysia and 
Indonesia. 
A positive impact is assigned when more 
than 55 percent of the factors have positive 
impact. An unknown impact is assigned 
when at least than 25 percent of the factors 
have an unknown impact and at least 45 
percent of the factors have positive impact 
or at least 35 percent of the factors have 
unknown impact and only 35 percent of 
factors have a negative impact. A negative 
impact is assigned if at least 45 percent of 
the factors have a negative impact. 
 
Category Malaysia  Indonesia  
Level 1 
Government 
Policy 
P: 87% (of 
factors have 
positive 
impact) 
P: 67% 
Regulatory 
Affairs 
U: 33% U: 25% 
Technology U: 83% U: 83% 
Localization 
Decision 
Framework 
Government 
Policy 
Regulatory 
Affairs 
Technology 
and Trade 
Demographics 
Competitors 
Foreign 
Direct 
Investment 
Longevity 
and Growth 
Supply 
Chain 
• Mainly through 
Literature Review Collect Data 
• Into eight pertinent 
categories 
Categorize 
Factors 
• Positive, Negative, or 
Unknown impact Analyze Factors 
• Using three levels based 
on importance of 
categories 
Develop 
Framework 
• To Malaysia and 
Indonesia 
Apply 
Framework 
and Trade 
Level 2 
Demographics U: 33% U: 40% 
Competitors P: 57% P: 57% 
Level 3 
FDI P: 100% U: 50% 
Longevity and 
Growth 
P: 100% P: 75% 
Supply Chain P: 80% P: 60% 
Notes: P – Positive, N – Negative, U - 
Unknown 
 
A category is given a “P” when majority 
of the factors under that category has a 
positive impact. A category is given an 
“N” when majority of the factors under 
that category has a negative impact. A 
category is given “U” when majority of the 
factors, about 55 percent of the factors, are 
neither positive nor negative. In such 
cases, the factors with unknown impact 
will determine the overall impact of that 
category. Therefore, such categories were 
given an unknown impact.   
Based on the analysis of the categories 
under Levels 1, 2 and 3 as well as the 
factors under each category, it can be 
inferred that Malaysia and Indonesia have 
a positive atmosphere for localization and 
it is recommended to localize in Malaysia 
and Indonesia provided that the internal 
factors in the company are also supportive.  
However, significant percentages of 
factors under Level 1, 2, and 3 have 
unknown impact on localization, and thus, 
it is important for Global Pharma to further 
explore the impact of unknown factors.  
 
Conclusions  
The decision framework application to 
Malaysia and Indonesia using external 
factors indicate that both countries have 
positive atmosphere to localize. As next 
steps, Global Pharma should perform the 
following: 
(1) Identify the factors with unknown 
impact. 
(2) Determine the impact of such 
factors either through market 
research or through surveys. 
(3) Update the impact based on the 
results from above steps. 
(4) Determine if the changes will 
impact the overall 
recommendation. 
The limitations of this thesis are: 
(1) Only external factors are 
considered. 
(2) The study is purely qualitative.
    
